More information


New Bone for Old Folks

Lorenz Hofbauer Group: New sclerostin antibody promotes bone formation and blocks bone resorption

Lorenz Hofbauer

Professor Lorenz Hofbauer, CRTD member and Director of the Center for Healthy Aging at Universitäts­klinikum Carl Gustav Carus, has completed a large clinical phase 3-study with colleagues from eight countries on over 7.000 women with osteoporosis. In the FRAME study, the monoclonal antibody against sclerostin named romosozumab was evaluated over one year in women with osteoporosis after menopause. Treatment with romosozumab reduced the risk of fractures by up to 73%. The study was published in the New England Journal of Medicine publiziert (DOI: 10.1056/NEJMoa1607948).

Further information at